OncoPharm cover image

Mirvetuximab Soravtansine

OncoPharm

00:00

Efficacy: Response Rates from Study 417

John asks about trial results and reports the phase 2 study showed about 32% overall response rate, mostly partial responses.

Play episode from 13:36
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app